Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Wuxi
Clinical trial register · China

Clinical Trials in Wuxi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 5582 Shanghai 3880 Guangzhou 3354 Hangzhou 1824 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Affiliated Hospital of Jiangnan University6 Sanofi5 Changhai Hospital4 Norroy Bioscience Co., LTD3 Wuxi People's Hospital3
Site location
Beijing5582 Shanghai3880 Guangzhou3354 Hangzhou1824 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Wuxi

84 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
6
Wuxi
2026-10-25
Recruiting
Norroy Bioscience Co., LTD
Phase 3
232
Nanjing, Wuxi
2026-08-31
Recruiting
FindCure Biosciences (ZhongShan) Co., Ltd.
Early Phase 1
13
Wuxi
2026-08-31
Recruiting
Ipsen
Phase 3
160
Guangzhou, Changsha, Nanjing, Wuxi, Jing’an, Chengdu, Hangzhou, Beijing
2026-08-25
Not yet open
Children's Hospital of Fudan University
Phase 3
120
Shanghai, Changsha, Guiyang, Wuhan, Wuxi, Xiamen
2026-08-20
Recruiting
Xijing Hospital
Observational
5,000
Zhaoqing, Xi'an, Jinan, Mianyang, Wuwei, Wuxi
2026-08-10
Recruiting
Norroy Bioscience Co., LTD
Phase 3
365
Nanjing, Wuxi
2026-08-06
Not yet open
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
NCT07764601Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
DrugsPenpulimab·Cytarabine·Methotrexate·Rituximab
WEI XU
Not applicable
58
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
2026-08
Recruiting
Affiliated Hospital of Jiangnan University
Early Phase 1
18
Wuxi
2026-07-30
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 1
30
Wuxi
2026-07-21
Recruiting
Bambusa Therapeutics
Phase 1/2
48
Wuhu, Beijing, Guangzhou, Shijiazhuang, Jinzhou, Wuxi, Taiyuan, Xi’an
2026-06-29
Recruiting
Jinling Hospital, China
Phase 2
75
Nanjing, Wuxi
2026-06-16
Recruiting
Xijing Hospital
Not applicable
10,000
Zhaoqing, Jinan, Mianyang, Wuwei, Wuxi
2026-06-15
Not yet open
Jiangsu Cancer Institute & Hospital
Phase 2
80
Changzhou, Huai'an, Lianyungang, Nanjing, Nantong, Suzhou, Wuxi, Xuzhou
2026-06-15
Recruiting
Synusight Biotech (Shanghai) Co., Ltd.
Phase 1
30
Wuxi, Shanghai
2026-06-15
Not yet open
Human Mass Balance Study of [¹⁴C]HRS-1893
NCT07656779Cardiomyopathies
Shandong Suncadia Medicine Co., Ltd.
Phase 1
6
Wuxi
2026-06
Recruiting
AbbVie
Phase 3
990
Beijing, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Wuxi, Changchun
2026-05-22
Recruiting
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
DrugTelitacicept
ADARx Pharmaceuticals, Inc.
Phase 2
30
Shenzhen, Guiyang, Zhengzhou, Baotou, Wuxi, Yantai, Beijing, Shandong
2026-05-21
Not yet open
Luye Pharma Group Ltd.
Phase 1
8
Wuxi
2026-04-30
Recruiting
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
NCT07459283Maligant Solid Tumor, Head & Neck Cancer, Thyroid Cancer, Lung Cancer - Non Small Cell Squamous
FindCure Biosciences (ZhongShan) Co., Ltd.
Early Phase 1
10
Wuxi
2026-04-20
Active, closed
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
6
Wuxi
2026-04-09
Not yet open
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
NCT07535710Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome, Cutaneous T Cell Lymphoma (CTCL)
DrugsAclarubicin·Vincristine·Prednisone·Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 1/2
37
Shanghai, Wuxi
2026-03-30
Not yet open
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
NCT07535762Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)
DrugsAclarubicin·Vincristine·Prednisone·Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 2
36
Shanghai, Wuxi
2026-03-30
Not yet open
Heilongjiang Feihe Dairy Co. Ltd.
Not applicable
124
Beijing, Foshan, Zhuhai, Xiangtan, Wuxi, Chengdu
2026-03-05
Not yet open
Shanghai Jiao Tong University School of Medicine
Not applicable
363
Nantong, Wuxi
2026-02-15
Not yet open
Portal Vein Thrombosis in Cirrhosis: Incidence, Outcomes and Anticoagulation
NCT07422701Portal Vein Thrombosis, Liver Cirrhosis
Peking University First Hospital
Observational
2,522
Beijing, Shenzhen, Hengshui, Qinhuangdao, Wuxi, Qingdao
2026-02-01
Recruiting
Nanolattix Biotechnology Co., Ltd.
Early Phase 1
10
Wuxi
2026-01-29
Recruiting
Sanofi
Phase 3
751
Guangzhou, Huizhou, Shanghai, Wuxi
2026-01-22
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Beijing, Changsha, Chengde, Chengdu, Guangzhou, Sanmenxia, Wuxi, Xi'an
2026-01-20
Recruiting
Sanofi
Phase 3
751
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hefei, Kunming, Shanghai
2026-01-16
Not yet open
Beijing Children's Hospital
Not applicable
2,650
Beijing, Chongqing, Guangzhou, Baoding, Zhengzhou, Wuxi, Changchun, Xi'an
2026-01-01
Recruiting
Sanofi
Phase 3
980
Xiamen, Guangzhou, Huizhou, Shenzhen, Wuhan, Changsha, Nanjing, Wuxi
2025-10-01
Recruiting
Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease
NCT07068438Chronic Bronchitis, COPD (Chronic Obstructive Pulmonary Disease)
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
210
Hefei, Beijing, Changzhou, Suzhou, Wuxi, Xuzhou, Nanchang, Hangzhou
2025-09-01
Recruiting
3D1015 Injection for Patients With mCRPC
NCT07537010Metastatic Castration-resistant Prostate Cancer, mCRPC
Chunjing Yu
Phase 1
8
Wuxi
2025-08-27
Recruiting
Climb Bio, Inc.
Phase 2
45
Beijing, Shenzhen, Wuxi, Jinan, Yantai, Yibin
2025-08-25
Active, closed
a2 Milk Company Ltd.
Not applicable
100
Foshan, Guangzhou, Wuxi, Xuzhou, Chengdu
2025-08-25
Recruiting
Bambusa Therapeutics
Phase 1
99
Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang
2025-08-09
Active, closed
Sanofi
Phase 2
105
Huizhou, Guangzhou, Nanjing, Suzhou, Wuxi, Shanghai, Hangzhou, Ningbo
2025-07-07
By invitation
Affiliated Hospital of Jiangnan University
Early Phase 1
10
Wuxi
2025-07-01
By invitation
Affiliated Hospital of Jiangnan University
Early Phase 1
20
Wuxi
2025-07-01
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Not yet open
Evaluation of AI-Generated Clinical Advice by Physicians
NCT06980467Artificial Intelligence (AI)
Tsinghua University
Not applicable
8
Beijing, Wuxi
2025-05-15
Recruiting
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 1/2
55
Wuxi, Tianjin
2025-05-14
Recruiting
Shanghai 6th People's Hospital
Observational
1,500
Wuxi
2025-04-13
Recruiting
Clinical Intelligent Management System Pragmatic RCT
NCT06893068Primary Care Diseases
Tsinghua University
Not applicable
204
Wuxi
2025-04-13
Recruiting
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Phase 1
76
Wuxi
2025-03-21
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Recruiting
Xinqiao Hospital of Chongqing
Not applicable
1,846
Wuhu, Chongqing, Jiangmen, Haikou, Huai'an, Wuxi, Jingdezhen, Dalian
2024-12-12
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Active, closed
Pfizer
Phase 3
636
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Recruiting
89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study
NCT06750419Clear Cell Renal Cell Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3
82
Beijing, Hangzhou, Hubei, Shanghai, Suzhou, Tianjin, Wuxi, Zhejiang
2024-11-06
By invitation
Affiliated Hospital of Jiangnan University
Not applicable
5
Wuxi
2024-10-29
Recruiting
FeNO Detection in Asthma Diagnosis: A New Technology Approach
NCT06852911Bronchial Asthma, Airway Disease
Novlead Inc.
Not applicable
170
Shanghai, Wuxi
2024-09-12
Recruiting
Wuxi People's Hospital
Not applicable
200
Wuxi
2024-05-07
Not yet open
Changhai Hospital
Not applicable
200
Guangzhou, Suzhou, Wuxi, Ningbo, Shanghai
2024-05-01
Active, closed
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
NCT06383052Metastatic Castration-resistant Prostate Cancer
Norroy Bioscience Co., LTD
Phase 1/2
30
Wuxi
2024-04-26
Recruiting
Guangzhou Zhiyi Biotechnology Co., Ltd.
Phase 3
1,298
Wuxi, Binzhou
2024-03-16
By invitation
Affiliated Hospital of Jiangnan University
Not applicable
50
Wuxi
2024-01-25
Recruiting
Bivision Pharmaceuticals, Inc.
Phase 1/2
90
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Wuxi
2023-12-22
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Fuzhou, Guangzhou, Changsha, Wuxi, Changchun, Jinan, Chengdu, Ürümqi
2023-12-07
Active, closed
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Recruiting
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
Wuxi People's Hospital
Not applicable
300
Wuxi
2023-09-04
Recruiting
Wuxi People's Hospital
Not applicable
200
Wuxi
2023-09-01
Recruiting
DualityBio Inc.
Phase 1/2
1,000
Zhengzhou, Changsha, Nanjing, Wuxi, Changchun, Shenyang, Shanghai, Chengdu
2023-08-17
Active, closed
Hoffmann-La Roche
Phase 3
459
Beijing, Cangzhou Shi, Shijiazhuang, Wuxi, Changzhou, Chengdu, Guangzhou, Hangzhou
2023-08-08
Recruiting
Affiliated Hospital of Jiangnan University
Not applicable
30
Wuxi
2023-07-12
Recruiting
Peking Union Medical College Hospital
Observational
336
Foshan, Guangzhou, Changsha, Wuxi, Jinan, Xi’an, Chengdu, Ürümqi
2023-06-29
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Guangzhou, Wuhan, Wuxi, Changchun, Chengdu, Hangzhou, Beijing, Shanghai
2022-12-09
Active, closed
National Vaccine and Serum Institute, China
Phase 3
13,500
Hechi, Hezhou, Lianyuan, Wuxi, Yongji, Yuncheng, Mianyang, Neijiang
2022-06-04
Recruiting
Shanghai Zhongshan Hospital
Observational
6,000
Xiamen, Guangzhou, Zhengzhou, Wuhan, Jiangyin, Wuxi, Yangzhou, Yixing
2022-05-01
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Beijing, Guangzhou, Changsha, Wuxi, Nanchang, Jinan, Chengdu, Yibin
2022-04-05
Active, closed
ITM Solucin GmbH
Phase 3
259
Shanghai, Wuxi
2021-12-21
Active, closed
argenx
Phase 3
173
Beijing, Bengbu, Huizhou, Shenzhen, Tianjin, Wuhan, Wuxi, Zhengzhou
2021-11-17
Active, closed
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
NCT04684108Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
61
Bengbu, Beijing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Xiangyang, Wuxi
2021-11-04
Active, closed
West China Hospital
Phase 3
554
Wuxi, Chengdu, Kunming
2021-08-26
Active, closed
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
NCT04807166Ovarian Neoplasms, Fallopian Tube Neoplasms, Neoplasms by Site, Genital Neoplasms, Female
DrugsCarboplatin/Paclitaxel·Anlotinib
Wenjun Cheng
Phase 2
56
Huai'an, Nanjing, Suzhou, Wuxi, Yancheng
2021-08-24
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
Fuzhou, Haikou, Zhengzhou, Changsha, Hengyang, Suzhou, Wuxi, Hangzhou
2018-11-28
Active, closed
Beijing Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Wuxi, Shanghai, Hangzhou
2018-06-29
Active, closed
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
360
Beijing, Wuhan, Changsha, Naning, Nanjing, Wuxi, Nanchang, Changchun
2017-05-12
Active, closed
Carotid Plaque Length to Predict Cardiovascular Events
NCT05409209Coronary Artery Disease
Changhai Hospital
Observational
3,000
Wuxi, Shanghai
2017-01-01
Active, closed
Association Between Carotid Plaque Length and Cardiovascular Outcomes
NCT05843487Coronary Artery Disease, Carotid Plaque
Changhai Hospital
Observational
3,000
Wuxi, Shanghai
2017-01-01
Active, closed
Changhai Hospital
Observational
3,637
Wuxi, Shanghai
2017-01-01
Active, closed
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
NCT02375620Short Stature Children Born Small for Gestational Age (SGA)
DrugPEG-somatropin
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
96
Beijing, Wuhan, Changsha, Wuxi, Nanchang, Changchun, Shanghai, Taiyuan
2015-04-23
Rows per page Showing 1–84 of 84
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/wuxi

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 84 of those studies with a site in Wuxi.

How many clinical trials are recruiting in Wuxi?

40 of the 84 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 14 have not yet opened recruitment, 25 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Wuxi), 84 studies
PhaseStudiesRecruitingShare
Phase 3231127.4%
Not applicable18921.4%
Phase 211313.1%
Phase 110511.9%
Observational9410.7%
Early Phase 1647.1%
Phase 1/2647.1%
Phase 2/3101.2%

Most active sponsors

Lead sponsors with the most studies (Wuxi)
Lead sponsorStudiesRecruiting
Affiliated Hospital of Jiangnan University62
Sanofi54
Changhai Hospital40
Changchun GeneScience Pharmaceutical Co., Ltd.30
Norroy Bioscience Co., LTD32
Novartis Pharmaceuticals30
Shanghai Jiao Tong University School of Medicine30
Wuxi People's Hospital33
AbbVie21
Bambusa Therapeutics22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.